Lipoproteins and Cardiovascular Health
Lipoproteins and Cardiovascular Health is a research topic within Surgery. Science Explorer counts 45k research works in it since 1950. 21.3% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the efficacy and safety of cholesterol-lowering treatments, particularly statins, in the prevention and management of cardiovascular diseases. It includes meta-analyses, clinical trials, guidelines, and genetic studies related to LDL cholesterol, atherosclerotic cardiovascular risk, hypercholesterolemia, and the role of C-reactive protein. The cluster also explores the impact of statins on various patient populations and their pleiotropic effects.
- Cholesterol-lowering
- Statins
- Cardiovascular Disease Prevention
- LDL Cholesterol
- Clinical Trials
- Atherosclerotic Cardiovascular Risk
- Hypercholesterolemia
- C-Reactive Protein
- Dyslipidaemias Management
- Genetic Variants
- Research works
- 45k fractional, since 1950
- In the world top 10%
- 9.7k per year above
- Top-10% rate
- 21.3% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +12% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Lipoproteins and Cardiovascular Health research?
By volume, the United States and China publish the most (1.5k and 929 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.5k works
- 2 China 929 works
- 3 Italy 364 works
- 4 India 332 works
- 5 United Kingdom 303 works
- 6 Japan 246 works
- 7 Spain 242 works
- 8 Germany 212 works
- 9 South Korea 209 works
- 10 Russia 199 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Lipoproteins and Cardiovascular Health research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Lipoproteins and Cardiovascular Health research, followed by Johns Hopkins University and Brigham and Women's Hospital.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 46 works
- 2 Johns Hopkins UniversityUnited States 31 works
- 3 Brigham and Women's HospitalUnited States 30 works
- 4 Fu Wai HospitalChina 27 works
- 5 University of MilanItaly 27 works
- 6 Harvard UniversityUnited States 26 works
- 7 University of North Carolina at Chapel HillUnited States 25 works
- 8 National Medical Research Center of CardiologyRussia 24 works
- 9 Capital Medical UniversityChina 23 works
- 10 InsermFrance 22 works
Who are the leading researchers in Lipoproteins and Cardiovascular Health?
The most-cited researchers publishing on Lipoproteins and Cardiovascular Health include Sadaf G Sepanlou, Erkin М Мirrakhimov and Paulo A. Lotufo.
- 1 Sadaf G Sepanlou Iran 8k citations
- 2 Erkin М Мirrakhimov Kyrgyzstan 7.8k citations
- 3 Paulo A. Lotufo Brazil 7.2k citations
- 4 Graeme J. Hankey Australia 7.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Lipoproteins and Cardiovascular Health research done?
The largest centres of Lipoproteins and Cardiovascular Health research in 2022–2025 are Beijing (China), Seoul (South Korea), London (United Kingdom) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Kanazawa.
Largest cities, 2022–2025
Where it is the local speciality
- KanazawaJP · 25.2 works14×
Location quotient: how much more of its research is in Lipoproteins and Cardiovascular Health than the world average.
Where is the best place to study Lipoproteins and Cardiovascular Health?
Among universities, judged by research, Medical University of Lodz, Chinese Academy of Medical Sciences & Peking Union Medical College and Monash University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Medical University of LodzPoland | 73.5 | 34.4% | 18.9× | 20 | +167.7% |
| 2 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 67.1 | 33.9% | 6.8× | 46 | +58.6% |
| 3 | Monash UniversityAustralia | 61.0 | 31.3% | 3.5× | 20 | +222.8% |
| 4 | University of MilanItaly | 58.5 | 27.7% | 5.9× | 27 | +82.0% |
| 5 | Western UniversityCanada | 58.4 | 36.2% | 4.6× | 18 | +111.2% |
| 6 | National and Kapodistrian University of AthensGreece | 57.6 | 32.4% | 5.1× | 18 | +132.7% |
| 7 | Johns Hopkins UniversityUnited States | 56.4 | 36.1% | 4.1× | 31 | +18.1% |
| 8 | Kanazawa UniversityJapan | 56.2 | 13.9% | 14.1× | 17 | +132.2% |
| 9 | Harvard UniversityUnited States | 56.1 | 40.3% | 3.0× | 26 | +7.0% |
| 10 | Imperial College LondonUnited Kingdom | 55.5 | 31.5% | 3.4× | 21 | +88.0% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Lipoproteins and Cardiovascular Health research growing?
Output in 2018–2022 was 12% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Lipoproteins and Cardiovascular Health.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.